Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Following guidelines from the Patient-Centred Outcomes Research Institute and using a mixed methods study, a new patient-reported outcome measure (PROM) for both nerve trauma and compression affecting the hand, the Impact of a Hand Nerve Disorders (I-HaND) Scale, was developed. Face-to-face interviews with 14 patients and subsequent pilot-testing with 61 patients resulted in the development of the 32-item PROM. A longitudinal validation study with 82 patients assessed the psychometric properties of the I-HaND. Content and construct validity was confirmed by cognitive interviews with patients and through principal component analysis. The I-HaND has high internal consistency (α = 0.98) and excellent test-retest reliability (intraclass correlation coefficient = 0.97). Responsiveness statistics showed that the I-HaND can detect change over 3 months and discriminate between improvers and non-improvers. We conclude that the I-HaND can be used as a PROM for people with a range of hand nerve disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1753193418780554 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selective inhibition of histone deacetylase 3 (HDAC3) prevents vincristine-induced peripheral neuropathy via macrophage polarization.
Neuropharmacology
September 2025
Metabolic Disorders and Neuroscience Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Sciences Pilani, Hyderabad campus, Hyderabad, India. Electronic address:
Neuroinflammation is vital in vincristine-induced peripheral neuropathy (VIPN). Locally infiltrated macrophages polarize to pro-inflammatory M1-type, release inflammatory cytokines, and contribute to neuropathic pain. Histone deacetylase 3 (HDAC3) regulates macrophage polarization.
View Article and Find Full Text PDFClinical outcomes of Hydrus Microstent implantation for open-angle glaucoma: Results from a large academic center.
Ophthalmol Glaucoma
September 2025
Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Purpose: To assess the clinical outcomes of Hydrus Microstent implantation with cataract extraction for the treatment of open angle glaucoma (OAG) over a maximum of 4 years.
Design: Retrospective, single-center, single-arm, longitudinal cohort study.
Subjects: 308 patients (464 eyes) with OAG who underwent Hydrus Microstent implantation with cataract extraction between February 2019 and December 2021, followed for a median (interquartile range, IQR) of 2.
Vagus nerve stimulation as a novel therapeutic approach for musculoskeletal diseases.
Am J Med Sci
September 2025
Department of Medicine, Division of Rheumatology, University of Oklahoma College of Medicine, Oklahoma City, OK; Department of Medicine, VAMC, Oklahoma City, OK. Electronic address:
Vagus nerve stimulation (VNS) has gained significant attention as a therapy for various medical conditions due to its ability to modulate chronic diseases, pain, and inflammation. VNS delivered by an implanted device is FDA approved for severe epilepsy and refractory depression. VNS delivered with implantable devices or transcutaneous methods are now being studied in several musculoskeletal diseases including osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, and fibromyalgia.
View Article and Find Full Text PDFRisdiplam and nusinersen in spinal muscular atrophy: a descriptive real-world study on motor function outcomes in northwestern Iran.
Neuromuscul Disord
August 2025
Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:
Spinal muscular atrophy (SMA) types 2 and 3 are chronic neuromuscular disorders characterized by progressive motor impairment. Although disease-modifying therapies such as risdiplam and nusinersen have shown clinical efficacy, real-world data in pediatric populations remain limited. This prospective observational study evaluated motor function outcomes in 20 children with SMA (aged 3 to 13 years; 12 with type 2, 8 with type 3) receiving either risdiplam or nusinersen in Northwestern Iran.
View Article and Find Full Text PDFStructured Symptom Assessment to Identify Patients With Small Fiber or Autonomic Neuropathy in Fibromyalgia.
Eur J Neurol
September 2025
Department of Neurology, Odense University Hospital, Odense, Denmark.
Background: Fibromyalgia (FM) is a complex chronic pain disorder characterized by widespread musculoskeletal pain and symptoms suggesting autonomic dysfunction. Small fiber neuropathy (SFN) has been described in a subgroup of patients. We aimed to explore the value of structured symptom assessment to identify patients with SFN or autonomic neuropathy.
View Article and Find Full Text PDF